BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36740149)

  • 1. Identification of methyltransferase modification genes associated with prognosis and immune features of pancreatic adenocarcinoma.
    Wang W; Zhang D; Chang D; Li Y; Ren L
    Mol Cell Probes; 2023 Feb; 67():101897. PubMed ID: 36740149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer.
    Guo Y; Wang R; Li J; Song Y; Min J; Zhao T; Hua L; Shi J; Zhang C; Ma P; Yang C; Zhu L; Gan D; Li S; Liu X; Su H
    Front Immunol; 2021; 12():769425. PubMed ID: 34804059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
    Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
    Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identify potential prognostic indicators and tumor-infiltrating immune cells in pancreatic adenocarcinoma.
    Shi T; Gao G
    Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35083488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N6-methyladenosine methylation modification patterns reveal immune profiling in pancreatic adenocarcinoma.
    Xu H; Yin L; Xu Q; Xiang J; Xu R
    Cancer Cell Int; 2022 May; 22(1):199. PubMed ID: 35606813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
    Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
    Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the m6A/m1A/m5C/m7G-related regulators on the prognosis and immune microenvironment of glioma by integrated analysis of scRNA-seq and bulk RNA-seq data.
    Yang L; Huang Z; Deng Y; Zhang X; Lv Z; Huang H; Sun Q; Liu H; Liang H; He B; Hu F
    J Gene Med; 2024 Feb; 26(2):e3666. PubMed ID: 38391150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of N6-Methyladenosine Modification Patterns and Tumor Immune Microenvironment in Pancreatic Adenocarcinoma.
    Liu Y; Li G; Yang Y; Lu Z; Wang T; Wang X; Liu J
    Front Genet; 2021; 12():752025. PubMed ID: 35046996
    [No Abstract]   [Full Text] [Related]  

  • 9. System Analysis Based on Pancreatic Cancer Progression Identifies BRINP2 as a Novel Prognostic Biomarker.
    Kang Y; Xu X; Liu J
    Crit Rev Eukaryot Gene Expr; 2023; 33(7):1-16. PubMed ID: 37602449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma.
    Chen Y; Lin X; Zou X; Qian Y; Liu Y; Wang R; Wang X; Yu X; Liu C; Cheng H
    BMC Gastroenterol; 2023 Apr; 23(1):113. PubMed ID: 37024802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular subtyping based on TRP family and prognostic assessment for TRP-associated lncRNAs in pancreatic adenocarcinoma.
    Li L; Xiao Z; He P; Zou W; Deng Z; Zhang G; Liu R
    BMC Gastroenterol; 2022 Nov; 22(1):454. PubMed ID: 36371178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of LAMA3/AC245041.2 gene pair associated with KRAS mutation and poor survival in pancreatic adenocarcinoma: a comprehensive TCGA analysis.
    Tian C; Li X; Ge C
    Mol Med; 2021 Jun; 27(1):62. PubMed ID: 34134622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening and validating the core biomarkers in patients with pancreatic ductal adenocarcinoma.
    Li Y; Zhu YY; Dai GP; Wu DJ; Gao ZZ; Zhang L; Fan YH
    Math Biosci Eng; 2019 Nov; 17(1):910-927. PubMed ID: 31731384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of a new molecular subtyping and prognostic signature with m6A/m5C/m1A/m7G regulatory genes for hepatocellular carcinoma.
    Liu T; Wang Y; Li Z; Sun L; Yang K; Chen J; Han X; Qi L; Zhou X; Wang P
    Heliyon; 2023 Nov; 9(11):e21285. PubMed ID: 38027812
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Kuang W; Wang X; Ding J; Li J; Ji M; Chen W; Wang L; Yang P
    Front Immunol; 2022; 13():805311. PubMed ID: 35154122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Analysis of 5-Methylcytosine (m
    Wang R; Guo Y; Ma P; Song Y; Min J; Zhao T; Hua L; Zhang C; Yang C; Shi J; Zhu L; Gan D; Li S; Li J; Su H
    Front Oncol; 2022; 12():851766. PubMed ID: 35433474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value and the Immune Microenvironment-associated Role of
    Song Y; Wang Y; Yu T; He Y; Wang C; Wang F; Zhou Y
    Anticancer Res; 2023 Dec; 43(12):5393-5408. PubMed ID: 38030175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive characterization of extracellular matrix-related genes in PAAD identified a novel prognostic panel related to clinical outcomes and immune microenvironment: A silico analysis with
    Chen X; Yuan Q; Liu J; Xia S; Shi X; Su Y; Wang Z; Li S; Shang D
    Front Immunol; 2022; 13():985911. PubMed ID: 36311789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of a novel N6-methyladenosine (m6A)-related multi- long non-coding RNA (lncRNA) prognostic signature in pancreatic adenocarcinoma.
    Yuan Q; Ren J; Li L; Li S; Xiang K; Shang D
    Bioengineered; 2021 Dec; 12(1):2432-2448. PubMed ID: 34233576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma.
    Yan C; Niu Y; Li F; Zhao W; Ma L
    J Transl Med; 2022 Oct; 20(1):455. PubMed ID: 36199146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.